

Corporate Presentation

NEO: AWKN

OTCQB: AWKNF

FWB: 954

January 2022

Awakn™

Disclaimer

GENERAL DISCLAIMER

This presentation of Awakn Life Sciences Corp. (the “Company”) is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly-available information, internally developed data, third party information and other sources. The third party information has not been independently verified. While the Company may not have verified the third party information, nevertheless, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. The information contained in this presentation does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in securities of the Company and is not to be considered as a recommendation by the Company that any person make an investment in the Company. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances.

Neither this presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and the Company does not accept liability to any person in relation thereto.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out below under the heading “Cautionary Note Regarding Forward Looking Information”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This presentation of the Company contains “forward-looking information”, which may include, but is not limited to, statements with respect to anticipated business plans or strategies of the Company, the listing of Company’s common shares on the NEO Exchange, the anticipated completion of clinical studies, the timing of any drug trials, the success of its pre-clinical and clinical trials, the ability to enter into acquisitions or collaborations to enhance its drug development platform, the success of any such acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by the Company or through such acquisitions or collaborations, the success or stage of development of discoveries or medicines, the progression of COVID-19 and its impacts on the Company’s ability to operate its assets, including the possible shutdown of facilities due to COVID-19 outbreaks, the Company’s ability to execute on the expansion of its digital platforms, risks associated with reliance on key personnel and risks associated with obtaining appropriate licensing. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “in ends”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian or UK laws and the uncertainty of existing protection from UK, Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the use of psychedelic therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. The foregoing factors are not intended to be exhaustive. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimate or intended.

Forward-looking statements contained herein are made as of the date of this presentation and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

Introduction

Awakn Life Sciences
is a biotechnology company,
Researching, Developing
and Delivering psychedelic
therapeutics to better
treat addiction.



Addiction – What and Why?



What is Addiction

Addiction is currently a poorly treated, chronic disease involving complex interactions among brain circuits, genetics, the environment, and an individual's life experiences.

People with addiction, use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.



Why Focus on Addiction

Addiction is one of the biggest unmet medical needs globally with substance and behavioral addictions affecting a significant proportion of the global adult population.



Market Opportunity

The global substance addiction treatment industry was valued at **US\$16bn** in 2021 and is forecast to increase to **US\$25bn** by 2027.

While we estimate the global addiction rehabilitation & recovery industry to be valued at **US\$140bn** per annum in 2021.

Business Model

Research & Development

The purpose of our R&D program is to develop world leading therapeutics to treat addiction.

- In the near term developing proprietary Ketamine-Assisted Therapies.
- In the medium term developing proprietary MDMA-Assisted Therapies.
- And longer term developing New Chemical Entities (NCE) to work in combination with our proprietary therapies.

Delivery

Clinics

Revenue generating: Q4 2021

- Treating addiction and other mental health conditions with our proprietary Psychedelic-Assisted Therapies.
- Generate real world data and evidence that supports our R&D activities.
- Generate free cash flow for the business.

Therapeutics Commercialization

Revenue generating: 2022

- Ketamine-Assisted Therapy for AUD – Commercialized through our licensing partnerships – 2022.
- Commercialize other Psychedelic -Assisted Therapies for addiction once developed through our R&D business.

Management



Anthony Tennyson
CO-FOUNDER & CHIEF EXECUTIVE OFFICER

Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland’s top ranked business school.



Jonathan Held
CO-FOUNDER & CHIEF FINANCIAL OFFICER

Jonathan is a chartered professional accountant, with CFO level experience for private / public companies.

Jonathan has worked in a number of sectors including technology, biotech and natural resources, both domestic and international, and has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings.



James Collins
CHIEF OPERATING OFFICER

James is a senior business leader and mental health champion with 17 years of experience with Accenture Strategy, 7 years as MD, designing and delivering corporate, digital and operating model strategies.

James holds a BSc and MPhil in Psychology from University College London (UCL).



Doriann Bailey
QUALITY, SAFETY & RISK LEAD

Doriann is passionate about the provision of high quality, safe, effective, caring, responsive and well led health-care services. She is a seasoned and highly effective strategic and operational senior professional. Doriann has over 30 years of clinical and managerial experience in various NHS and Independent organisations.

As well as being a Specialist Advisor (Governance) for The Care Quality Commission (CQC), Doriann is a qualified nurse and midwife.



Prof. David Nutt
CHIEF RESEARCH OFFICER

David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books, including one for the general public, *Drugs: Without The Hot Air*, that won the Transmission Prize in 2014.



Prof. Celia Morgan
HEAD OF KETAMINE ASSISTED PSYCHOTHERAPY FOR ADDICTION

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship programme at Yale University. After completing her Ph.D Prof. Morgan worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.



Dr. Ben Sessa
CO-FOUNDER & CHIEF MEDICAL OFFICER

Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of Drug-Assisted Therapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.



Dr. Laurie Higbed
LEAD PSYCHOLOGIST

Laurie is an experienced clinical psychologist. Laurie has worked as a lead therapist on clinical trials using MDMA and Psilocybin-Assisted Therapy and has a special interest in working with complex trauma, addictions and the use of psychedelic therapy to treat a range of mental health difficulties.

Laurie is registered with the Health and Care Professions Council (HCPC) and is a member of the Association of Clinical Psychologists (ACPUK).



Gordo Whittaker
CHIEF MARKETING OFFICER

Gordo is a senior marketing and communications industry leader with over 10 years’ experience, building, protecting and growing some of the world’s most famous brands, including Volkswagen and Land Rover, where he led their global advertising function.



Kate Butler
VICE PRESIDENT – FINANCE

Kate is a Chartered Accountant with significant experience of both UK and US public companies. Kate has worked across a number of sectors including pharmaceuticals and natural resources. Most recently Kate has held senior positions at Vectura Group plc, a FTSE 250 specialist inhalation contract development and manufacturing organisation, and Gilead Sciences Inc, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Kate has extensive experience of building strong finance teams and processes, and growing companies in new markets.



Dr. Shaun McNulty
CHIEF SCIENTIFIC OFFICER

Shaun is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of industry experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Davis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies. Shaun has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.



Martyna Kabia
HR LEAD

Martyna is a highly motivated and career driven HR Professional with over 20 years’ proved ability gained in the NHS, higher education, Faith based, private and public sector. She is experienced in key areas of strategic HR management including recruitment and selection, employee relations, employment law, analysis and reporting, remuneration, job evaluation, project work, training, coaching, mentoring and HR consultancy.

Corporate Board



George Scorsis
CO-FOUNDER & CHAIRMAN
CORPORATE BOARD

George has 15 years experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks and, most recently, medical cannabis. Formerly President of Red Bull Canada, he was instrumental in restructuring the organisation and growing the business to \$150 MM in revenue.



Anthony Tennyson
CO-FOUNDER & CHIEF EXECUTIVE OFFICER

Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland's top ranked business school.



Paul Carter
INDEPENDENT NON-EXECUTIVE DIRECTOR
CORPORATE BOARD

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, having served as Executive Vice-President and Chief commercial Officer of Gilead Sciences Inc. He also was the head of GSK China amongst many others executive positions. He currently sits on the board of several publicly listed and private bioscience companies.



Stephen Page
INDEPENDENT NON-EXECUTIVE DIRECTOR
CORPORATE BOARD

Stephen Page has worked at Chief Executive and Board level in UK healthcare for over 30 year, most noticeably leading Priory Healthcare, the largest network of mental healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organisations in both public and private sectors including Oxleas NHS Trust in London, Nestor plc and Acorn Care and Education.



Prof. John Papastergiou
INDEPENDENT NON-EXECUTIVE DIRECTOR
CORPORATE BOARD

Professor John Papastergiou is a highly regarded pharmacist and clinical research scientist who has served as an advisor to several leading pharmaceutical organisations including Bayer, Pfizer, GSK, and Astra Zeneca. He holds faculty appointments at the schools of Pharmacy at both the University of Toronto and the University of Waterloo. In 2019, he was named by the International Forum on Advancement of Healthcare as one of the top 100 healthcare leaders globally.

Key Scientific Advisors



Prof. Barbara J. Mason
ADVISOR
CLINICAL ADVISORY BOARD

Barbara J. Mason, Ph.D. is Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Pearson Family Professor in the Department of Molecular Medicine at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of substance use disorder has been recognized globally. Prof. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence.



Prof. Harriet de Wit
ADVISOR
PRE-CLINICAL ADVISORY BOARD

Prof. de Wit is the Professor and Director of the Human Behavioral Pharmacology Laboratory in the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago. In addition to her role as Principal Investigator for several NIH-funded research projects, Dr. de Wit serves as Field Editor for the journal Psychopharmacology. She is also a consultant to the Food and Drug Administration (FDA).



Prof. Matt Johnson
ADVISOR
CLINICAL ADVISORY BOARD

Prof. Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world's most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioural economics of drug use, addiction, and risk behavior.



Ann Mithoefer, BSN
ADVISOR
CLINICAL ADVISORY BOARD

Ann Mithoefer, B.S.N., is a Registered Nurse focused primarily on training and supervising therapists conducting MAPS-sponsored clinical trials, as well as continuing to conduct some MAPS research sessions. Between 2004 and 2018, she and her husband, Michael Mithoefer, M.D., completed two of the six MAPS-sponsored phase-II clinical trials testing MDMA-Assisted Therapy for PTSD, as well a study providing MDMA-Assisted sessions for therapists who have completed the MAPS Therapist Training, and a pilot study treating couples with MDMA-Assisted Therapy combined with Cognitive-Behavioural Conjoint Therapy.



Dr. Michael Mithoefer
ADVISOR
CLINICAL ADVISORY BOARD

Michael Mithoefer, M.D., began collaborating with MAPS in 2000 on the first U.S. phase-II clinical trial of MDMA-Assisted Therapy. He has since conducted two of the six MAPS sponsored phase-II clinical trials testing MDMA-Assisted Therapy for PTSD, as well a study providing MDMAassisted sessions for therapists who have completed the MAPS-sponsored MDMA Therapy Training Program, and a pilot study treating couples with MDMA-Assisted Therapy combined with Cognitive-Behavioural Conjoint Therapy.




Prof. Stephen Husbands
ADVISOR
PRE-CLINICAL ADVISORY BOARD

Professor Husbands is professor of medicinal chemistry in Department of Pharmacy and Pharmacology at the University of Bath. His research has focused on the development and therapeutic potential of central nervous system targeted ligands, particularly those interacting with multiple receptors.

Our Approach to Addiction



Prevalence of Addiction



For references see slide 31

Our Approach – The Solution

Awakn is addressing addiction with new proprietary combined therapeutics (drugs and therapies) that approach the treatment of addiction in a radically different way than before.


What are we doing differently?

Based on new research, Awakn's drugs will target the brain circuits that drive addiction through multiple receptors rather than single drug receptors. These circuits control the behavioral drivers of addiction. By focusing on circuit mechanisms rather than isolated receptors Awakn's approach has the potential to be effective in the treatment of both substance and behavioral addictions.

This disruption allows the individual to escape from the repetitive addictive behaviors and thoughts, and in doing so engage with a psychotherapeutic process to enable lasting positive change.

Medicine and therapy (therapeutics)

This is where Awakn's proprietary therapy comes in. Our therapies work in conjunction with our medicines, enabling the patients to regain control over their lives and helping them to learn new more adaptive ways to respond to addictive urges, cravings and the underlying processes that drive them.



NUCLEUS ACCUMBENS (NACC) & VENTRAL PALLIDUM (VP)

ORBITOFRONTAL CORTEX (OFC)


PREFRONTAL CORTEX (PFC)

HIPPOCAMPUS (HIP) & AMYGDALA (AMYG)

Our Approach – The Solution


Balanced brain state – no addiction

Cognitive control (PFC) controls the final decision making.




Addicted brain

Excessive drives from memory and reward/pleasure circuits depress cognitive control and enhance the drive and salience functioning so the cognitive control no longer controls the behaviour.



Our Approach – The Solution

Where Awakn treatments act to disrupt these addiction circuits to restore balance in the brain



NUCLEUS ACCUMBENS (NACC) & VENTRAL PALLIDUM (VP)

PREFRONTAL CORTEX (PFC)

ORBITOFRONTAL CORTEX (OFC)

HIPPOCAMPUS (HIP) & AMYGDALA (AMYG)

Research & Development



Therapeutics Development Strategy

Our research team consists of world leading experts in the fields of drug development, clinical research, psychiatry, psychotherapy and neurochemistry.

Our team, is building a pipeline of new therapeutics (drugs and therapies to be used in combination).

We will focus our research activities on treating addictions where the consequences for the patient, their family and society are at present most severe, with **Near**, **Medium**, and **Long-Term** programs.

NEAR TERM

Ketamine–Assisted Therapy

Alcohol Use Disorder (AUD) – phase-IIa/b complete

Behavioral Addictions – Clinical Development

(Including Gambling Disorder, Binge Eating Disorder, Internet Gaming Disorder and Compulsive Sexual Behavior).

MEDIUM TERM

MDMA–Assisted Therapy

Alcohol Use Disorder – phase-IIa complete

LONG TERM

New Chemical Entities

Develop Proprietary NCE's and Therapies to treat addiction more effectively and efficiently than currently available treatments.

Progress: Our Pipeline



Ketamine Research Program

Alcohol Use Disorder:

- Awakn acquired the exclusive rights to the worlds only phase-IIa/b clinical trial for Ketamine-Assisted Therapy to treat AUD, led by world renowned ketamine expert, Prof. Celia Morgan who is also Awakn's Head of Ketamine-Assisted Therapy for addiction.
- Results from the successful phase-IIb trial were published in January 2022 in the American Journal of Psychiatry.
- Awakn has signed a MOU with the NHS in the UK to bring forward research in to phase-III and assess the organizational readiness of the NHS to adopt the treatment.
- Awakn is now assessing how to progress the phase-IIb into a pivotal phase-III trial.

Behavioral Addictions:


- Awakn Initiated the first-ever ketamine treatment study for Gambling Disorder led by Professor Celia Morgan in August 2021.
- In January 2022 the study was broadened to include:
 - Binge Eating Disorder.
 - Compulsive Sexual Behavior (including pornography addiction).
 - Internet Gaming Disorder.

Phase-IIa/b – Ketamine-Assisted Therapy for AUD

Primary Outcome: Days Abstinent


The KARE therapy produced a statistically significant increase in percentage days abstinent in comparison to the placebo and education group. With 86% abstinence observed in the KARE therapy arm, this is more than double the 38% abstinence observed in a similar group of patients receiving industry standard treatment as usual in the US.

** Treatment as usual specialist outpatient alcohol care in US taken from a trial (Oslin et al. 2013) was chosen as a descriptive comparator as KARE will likely be delivered in outpatient settings.*




Phase-IIa/b – Ketamine-Assisted Therapy for AUD

Co-Primary Outcome: Relapse



Exploratory Analysis: Number of Days Heavy Drinking



On average the KARE group were 2.7 times more likely than the placebo education group and 2.5 times more likely than the industry standard treatment as usual study group to relapse. Heavy Drinking Days, defined as 65g of alcohol for men, 52g for women in a single day, is an FDA and EMA regulatory endpoint guideline.

While not one of the trials primary endpoints, we saw a statistically significant reduction in ‘Heavy Drinking Days’ when comparing KARE to placebo and education group. When comparing KARE to the industry standard treatment as usual in the US, we can see 77% reduction in Heavy Drinking Days. Heavy Drinking Days is a primary endpoint used by EMA and FDA when assessing marketing authorization/ regulatory approval.

** Treatment as usual specialist outpatient alcohol care in US taken from a trial (Oslin et al. 2013) as KARE will likely be delivered in outpatient settings.*

MDMA Research Program

Assets acquired:


- Awakn has acquired the exclusive rights to the worlds only phase-IIa clinical trial for MDMA-Assisted Therapy to treat Alcohol Use Disorder led by world renowned addiction experts, Prof. David Nutt, Dr. Ben Sessa, Dr. Laurie Higbed.
- The team who led this trial Prof. David Nutt, Dr. Ben Sessa and Dr. Laurie Higbed all now work for Awakn.

Current activity:

- Progressing the BIMA trial into phase-IIb clinical trial for MDMA-Assisted Therapy in treating patients with Alcohol Use Disorder. This will be a two armed Randomized Trial. N= 120.
- Awakn has signed a MOU with MAPS to explore a data licensing agreement and a partnership to secure marketing authorisation/regulatory approval for the commercialization of MDMA-assisted therapy for the treatment of AUD in Europe.

Planned future activity:

- Seek to secure marketing autoriazation/regulatory approval for MDMA to treat AUD in the UK and EU.



NCE Research Program


Assets acquired:

- Awakn has acquired six years of proprietary research data from Prof. David Nutt, who is now Awakn’s Chief Research Officer.
- This data describes newly discovered modes of action for MDMA and potentially faster acting entactogenic compounds, facilitating our NCE programme.

Current status:

- Hit to Lead program completed with our research partner Evotec.
- In vitro and in vivo data shows efficacy for drug-like hits, defining chemical series for lead optimization.
- Patents filed.
- Lead Optimisation initiating Q1 2022.

Planned future activity:



Delivery: Clinics



Delivery: Clinics

awaknclinics.com

Providing hope for those for whom the status quo is not working by combining the proven therapeutic potential of psychedelics with therapy to treat addiction and other mental health conditions.

Each Awakn Clinic will be owned and operated by Awakn, will be led by a consultant psychiatrist, will deliver Ketamine-Assisted Therapy in the near term, and will utilize MDMA when Awakn secures marketing authorization.

2021

Europe & United Kingdom

- Oslo – Open
- Bristol – Open

2022

Europe & United Kingdom

- London #1
- Manchester
- London #2
- Birmingham
- UK clinic x 1
- Nordics x 1
- Dublin, Ireland

2023+

Europe

- Nordic's x 3
- DACH (Germany, Austria, Switzerland)
- Benelux (Belgium, Netherland, Luxembourg)
- France

Delivery: Clinics

awaknclinics.com

Our target is **20 clinics by the end of 2024**, with an average of 6 treatment rooms per clinic.

Treatment programs will cost between £6,000 – £7,500. Each treatment program will consist of 3-4 ketamine sessions and 8 therapy and integration sessions.

We will deliver approximately 8 patient treatment programs, per treatment room, per month.

Each clinic will generate on **average £3m revenue per annum**.



Delivery: Therapeutics Commercialization



Licensing Partnerships: Starting 2022

Purpose:

- To commercialize Ketamine-Assisted Therapy for Alcohol Use Disorder.

Target Audience:

- Addiction treatment clinic's in the US and Canada.

Licensing partnerships outside UK and Europe for the Awakn KARE methodology.

Proposition:



Access to KARE proprietary IP



Systems



Training



Clinic design

Awakn in the Media



Cap Table

Capital Structure
















Common Shares	24,887,307
Warrants	1,822,785
Stock Options	2,009,828
DSU's	35,172
Full Diluted	28,755,092
No Debt	
Management / Insider Ownership	23.64%
Escrowed Shares	65.12%

Progress vs Competitor Landscape

Competitive Landscape In Psychedelics

	PRECLINICAL PROGRAM	PHASE I	PHASE IIA	PHASE IIB	PHASE III
ADDICTION	Cybin Awakn™	MindMed	Awakn™	Awakn™	
ANXIETY	Cybin		MindMed		
DEPRESSION	field trip Small Pharma	BIOMIND A LIFE SCIENCES COMPANY Small Pharma	Cybin	COMPASSION' Navigating Mental Health Pathways	
EATING DISORDERS			COMPASSION' Navigating Mental Health Pathways MAPS		
PTSD		MindMed			MAPS
OTHER	Cybin Mindset Pharma Inc. wesana™		MindMed COMPASSION' Navigating Mental Health Pathways		

Comparables

	PRECLINICAL PROGRAM	PHASE I	PHASE IIA	PHASE IIB	PHASE III	FULLY DILUTED MARKET CAP
COMPASS			 COMPASSION' <small>Navigating Mental Health Pathways</small>	 COMPASSION' <small>Navigating Mental Health Pathways</small>		CA\$1,001M
MINDMED		 MindMed	 MindMed			CA\$690M
CYBIN	 Cybin		 Cybin			CA\$275M
FIELDTRIP	 field trip					CA\$165M
BIOMINDLABS		 BIOMIND <small>A LIFE SCIENCES COMPANY</small>				CA\$101M
AWAKN LIFE SCIENCES	 Awakn™		 Awakn™	 Awakn™		CA\$82M
MINDSETPHARMA	 Mindset Pharma Inc.					CA\$81M
SMALL PHARMA	 Small Pharma	 Small Pharma				CA\$80M
WESANAHEALTH	 wesana™					CA\$41M

Market cap as per Jan 7th, source Stoic Advisory Inc.

Why Invest in Awakn?

Multiple Scalable Revenue Streams:

- Clinics from 2021.
- Therapeutics Commercialization from 2022.



Our Focus – Addiction (Substance and Behavior)

- One of the biggest unmet medical needs of our times.
- Current treatment options have limited efficacy.
- Significant current and future market opportunity.
- De-risking our future activity: Human Proof of Concept shown for entactogens in our clinical trials (KARE, BIMA)



A Revolutionary Approach

- Targeting brain circuits rather than individual receptor sites.
- Combined novel therapeutics – drugs and therapies used in combination.
- Potential to treat both substance and behavioral addictions.



IP Portfolio

- 5 patent families filed
- 2 more families in preparation covering multiple chemical series and clinical indications
- A completed phase-IIa/b trial for Ketamine-Assisted Therapy to treat AUD.
- A planned phase-IIb trial for MDMA as a treatment for AUD with ethics approval forecast for Q4 2021.



Team

Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Dr. Shaun McNulty, Prof. Barbara J. Mason and Prof. Harriet de Wit.



Global Research Leaders in the Field of Psychedelic Treatments for Addiction:

- Prof. Celia Morgan led the world's only Ketamine-Assisted Therapy for AUD study (KARE).
- Prof. David Nutt and Dr. Ben Sessa led the world's only MDMA-Assisted Therapy for AUD study (BIMA)



References

In relation to references on slide 9

INDICATIONS	SCOPE	SOURCE
ALCOHOL USE DISORDER	GLOBAL	Global Burden of Alcohol Use Disorders and Alcohol Liver Disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966598/
TABACCO USE DISORDER	GLOBAL	Tobacco Use Worldwide: Legislative Efforts to Curb Consumption https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748295/
OPIOID USE DISORDER	GLOBAL	The Lancet - The Global Burden of Diseases, Injuries, and Risk Factors Study https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(19)32229-9.pdf
GAMBLING DISORDER	GLOBAL	Problem gambling worldwide: An update and systematic review of empirical research (2000–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370365/
COMPULSIVE SEXUAL BEHAVIOUR	GLOBAL	Epidemiology, Prevalence, and Natural History of Compulsive Sexual Behaviour https://www.sciencedirect.com/science/article/abs/pii/S0193953X08000725
BINGE EATING DISORDER	GLOBAL	The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys https://pubmed.ncbi.nlm.nih.gov/23290497/
INTERNET GAMING DISORDER	GLOBAL	Global prevalence of gaming disorder: A systematic review and meta-analysis https://pubmed.ncbi.nlm.nih.gov/33028074/

Enquiries

Investor Enquiries:

KCSA Strategic Communications

Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:

America and Canada:
KCSA Strategic Communications

Anne Donohoe
Adonohoe@KCSA.com

Rest of World:

ROAD Communications

Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk



Awakn™